If results translate beyond in vitro cell culture, this finding has implications for the design of treatment strategies in HER2+ cancers, as multiple PI3K/AKT/MTOR inhibitors are being tested in HER2+ cancers, and MEK inhibitors are being tested in a variety of other tumor types [12]. This evidence concerns the gene MAP2K7 and cancer.